Pharsight

1. Eprontia patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11826343	AZURITY	Compositions and methods for treating epilepsy, seizures and other conditions	Aug, 2040 (16 years from now)
US11633374	AZURITY	Compositions and methods for treating epilepsy, seizures and other conditions	Aug, 2040 (16 years from now)
US11433046	AZURITY	Compositions and methods for treating epilepsy, seizures and other conditions	Aug, 2040 (16 years from now)

Market Authorisation Date: 05 November, 2021

Treatment: Indicated for the preventive treatment of migraine in patients 12 years and older

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg/mL	06 Oct, 2022	1		21 Aug, 2040

Strength	Dosage	Availability
25MG/ML	SOLUTION;ORAL	Prescription

EPRONTIA family patents

2. Qudexy Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10363224	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)
US9555005	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)
US8652527	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)
US8889190	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)
US9101545	UPSHER SMITH LABS	Extended-release topiramate capsules	Mar, 2033 (8 years from now)

Market Authorisation Date: 11 March, 2014

Treatment: Treatment of seizures

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg, 50 mg, 100 mg, 150 mg, and 200 mg	24 Dec, 2015	1		19 Mar, 2033	Extinguished Non-Forfeiture

Strength	Dosage	Availability
150MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
200MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

QUDEXY XR family patents

3. Topamax patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5998380	JANSSEN PHARMS	Treatment of migraine	Oct, 2015 (8 years ago)
US7498311	JANSSEN PHARMS	Treatment of migraine	Oct, 2015 (8 years ago)
US7018983	JANSSEN PHARMS	Treatment of migraine	Oct, 2015 (8 years ago)
US6503884	JANSSEN PHARMS	Migraine treatment method using topiramate and related compounds	Oct, 2015 (8 years ago)
US7018983 (Pediatric)	JANSSEN PHARMS	Treatment of migraine	Apr, 2016 (8 years ago)
US5998380 (Pediatric)	JANSSEN PHARMS	Treatment of migraine	Apr, 2016 (8 years ago)
US7498311 (Pediatric)	JANSSEN PHARMS	Treatment of migraine	Apr, 2016 (8 years ago)
US6503884 (Pediatric)	JANSSEN PHARMS	Migraine treatment method using topiramate and related compounds	Apr, 2016 (8 years ago)
US7125560	JANSSEN PHARMS	Pharmaceutical composition of topiramate	Mar, 2019 (5 years ago)
US7125560 (Pediatric)	JANSSEN PHARMS	Pharmaceutical composition of topiramate	Sep, 2019 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jul 15, 2014
Pediatric Exclusivity(PED)	Jun 22, 2013
M(M-54)	Dec 22, 2012

Market Authorisation Date: 24 December, 1996

Treatment: Prophylactic treatment of migraine; Treatment of seizures

Dosage: TABLET;ORAL; CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15 mg and 25 mg	07 Sep, 2005	1	15 Apr, 2009	01 Sep, 2019	Eligible
25 mg, 100 mg and 200 mg	26 Dec, 2001
50 mg	08 Sep, 2005	1	27 Mar, 2009	26 Sep, 2008	Extinguished

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Discontinued
400MG	TABLET;ORAL	Discontinued
25MG	CAPSULE;ORAL	Prescription
15MG	CAPSULE;ORAL	Prescription
50MG	TABLET;ORAL	Prescription

TOPAMAX family patents

4. Topamax Sprinkle patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5998380	JANSSEN PHARMS	Treatment of migraine	Oct, 2015 (8 years ago)
US7498311	JANSSEN PHARMS	Treatment of migraine	Oct, 2015 (8 years ago)
US7018983	JANSSEN PHARMS	Treatment of migraine	Oct, 2015 (8 years ago)
US6503884	JANSSEN PHARMS	Migraine treatment method using topiramate and related compounds	Oct, 2015 (8 years ago)
US5998380 (Pediatric)	JANSSEN PHARMS	Treatment of migraine	Apr, 2016 (8 years ago)
US6503884 (Pediatric)	JANSSEN PHARMS	Migraine treatment method using topiramate and related compounds	Apr, 2016 (8 years ago)
US7018983 (Pediatric)	JANSSEN PHARMS	Treatment of migraine	Apr, 2016 (8 years ago)
US7498311 (Pediatric)	JANSSEN PHARMS	Treatment of migraine	Apr, 2016 (8 years ago)
US7125560	JANSSEN PHARMS	Pharmaceutical composition of topiramate	Mar, 2019 (5 years ago)
US7125560 (Pediatric)	JANSSEN PHARMS	Pharmaceutical composition of topiramate	Sep, 2019 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jul 15, 2014
Pediatric Exclusivity(PED)	Jun 22, 2013
M(M-54)	Dec 22, 2012

Market Authorisation Date: 26 October, 1998

Treatment: Prophylactic treatment of migraine; Treatment of seizures

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
15 mg and 25 mg	07 Sep, 2005	1	15 Apr, 2009	01 Sep, 2019	Eligible

Strength	Dosage	Availability
50MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE;ORAL	Discontinued

TOPAMAX SPRINKLE family patents

5. Trokendi Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8889191	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (3 years from now)
US8663683	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (3 years from now)
US10314790	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (3 years from now)
US8298580	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (3 years from now)
US9622983	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (3 years from now)
US9555004	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (3 years from now)
US8877248	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (3 years from now)
US9549940	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (3 years from now)
US8992989	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (3 years from now)
US8298576	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Apr, 2028 (3 years from now)

Market Authorisation Date: 16 August, 2013

Treatment: Use of trokendi xr for prophylactic treatment of migraine; Treatment of epilepsy; Use of trokendi xr for the treatment of epilepsy